Navigation Links
ViroPharma Reports Results of Phase 3 Clinical Trial for Maribavir in Bone Marrow Transplant Patients
Date:2/9/2009

- Conference Call at 10:00 A.M. Today to Discuss Results -

EXTON, Pa., Feb. 9 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that its Phase 3 trial evaluating maribavir used as prophylaxis in allogeneic stem cell, or bone marrow, transplant (SCT) patients did not achieve its primary endpoint. In the primary analysis, there was no statistically significant difference between maribavir and placebo in reducing the rate of CMV disease. In addition, the study failed to meet its key secondary endpoints. Maribavir was generally well tolerated in this clinical study.

"We are extremely disappointed by the outcome of this pivotal study," said Vincent J. Milano, ViroPharma's president and chief executive officer. "We just received these data and there are far more questions than answers; we still have a significant amount of work to do to fully understand this outcome and its impact on the overall program. Our disappointment is no doubt shared by physicians and transplant patients, who must today contend with CMV disease."

The primary endpoint of this Phase 3 study was the incidence of CMV disease, confirmed by an independent endpoint committee, within 6 months post-transplant. The incidence of CMV disease within 6 months was 4.4 percent for maribavir compared to 4.8 percent for placebo (P=0.79). The first of four key secondary endpoints was the rate of initiation of anti-CMV treatment within 6 months, which was 37.9 percent for maribavir compared to 40.5 percent for placebo (P=0.49). In addition, the incidence of graft-versus-host disease, mortality and CMV disease-free survival was comparable between the groups.

Conference Call and Webcast

ViroPharma is hosting a live teleconference and webcast with se
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. ViroPharma to Present at the 27th Annual J.P. Morgan Healthcare Conference
2. ViroPharma Provides Update on Vancocin(R)
3. ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema
4. ViroPharma To Present At The 20th Annual Piper Jaffray Healthcare Conference
5. ViroPharma to Discuss Commercialization and Launch of Cinryze(TM) on November 5, 2008
6. ViroPharma Incorporated Reports Third Quarter 2008 Financial Results
7. ViroPharma to Release 2008 Second Quarter Financial Results on July 30, 2008
8. ViroPharma Incorporated Reports First Quarter 2008 Financial Results
9. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2007 Financial Results
10. Vincent J. Milano to Succeed Michel de Rosen as President and Chief Executive Officer of ViroPharma
11. ViroPharma Provides Update on Vancocin(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... 2014 Online retailer Disposable Medical Express ... price guarantee on their inventory of Tranquility incontinence care ... and pads along with other personal care products. ... find a line of incontinence products that you love,” ... that works for you, you shouldn't have to compromise ...
(Date:8/1/2014)... 01, 2014 Stress management can be difficult ... hours of concentration and diminish rest and leisure time, stress ... is critical to find a way to manage stress in ... life. , “Having a good sense of work-life balance is ... Jacobs, founding clinician of SF Custom Chiropractic. “Stress, left ...
(Date:7/31/2014)... Seattle, WA (PRWEB) July 31, 2014 ... summer, Duke’s Chowder House is featuring new ... available at all six Duke’s locations throughout ... and out-of-town guests alike, Duke’s award-winning, customer-nominated Seattle’s best ... outdoor decks. To celebrate its Lake Union location’s 25th ...
(Date:7/31/2014)... (August 1, 2014) If you have asthma, you may ... to help you recognize and respond to changes and understand ... you,re in the green zone, you,re doing well, yellow means ... means you require urgent care. New guidelines are now available ... zone, back into green and away from the red zone. ...
(Date:7/31/2014)... 01, 2014 The 2013 PolyU ... 0.89 points from 75.07 in 2012. The index ... sectors and integrates them into an overall index. ... increasingly more satisfied with Hong Kong over time. ... excelling in service performance in Hong Kong are ...
Breaking Medicine News(10 mins):Health News:Disposable Medical Express Offering Low Price Guarantee On Tranquility Products 2Health News:SF Custom Chiropractic Celebrates National Relaxation Day and the Benefits of Massage Therapy for the Month of August 2Health News:Seattle Seafood Restaurant Lake Union Duke's Chowder House Celebrating its 25th Anniversary, Still a Best Outdoor Deck Spot to Sip Up Cocktails in Record-Breaking Heat. 2Health News:Seattle Seafood Restaurant Lake Union Duke's Chowder House Celebrating its 25th Anniversary, Still a Best Outdoor Deck Spot to Sip Up Cocktails in Record-Breaking Heat. 3Health News:PolyU Released Report On 2013 Tourist Satisfaction and Tourism Service Quality Indices to Boost Tourism Development 2Health News:PolyU Released Report On 2013 Tourist Satisfaction and Tourism Service Quality Indices to Boost Tourism Development 3
... August 3, 2011 A woman,s ethnicity as well as ... for hereditary breast cancer. Research into understanding and treating hereditary ... Hope conference, a scientific meeting hosted by the Department of ... 10 percent of breast cancers are thought to be hereditary, ...
... urine test to detect and monitor the effectiveness of treatment ... developing world. Their study appears in the ACS, journal ... Singh Chauhan and Ranjan Kumar Nanda notes that TB strikes ... year, mostly in developing countries. Health care workers diagnose the ...
... of several well-known safety procedures could greatly reduce patient-harming ... according to a new study led by Johns Hopkins ... quality assurance (QA) checks to prevent radiotherapy errors, but ... systematically evaluated their effectiveness. Working with researchers at Washington ...
... America (GSA) the nation,s largest interdisciplinary organization devoted ... Binstock, PhD, of Case Western Reserve University as the ... This distinguished honor recognizes a significant contribution in ... treatment, practice or service, prevention, amelioration of symptoms or ...
... (GSA) the nation,s largest interdisciplinary organization devoted ... Jette, PhD, of Boston University as the 2011 recipient ... This distinguished honor is given annually to acknowledge ... work may be in any or all of the ...
... Society of America (GSA) the nation,s largest ... has chosen Eva Kahana, PhD, of Case Western Reserve ... Contribution to Gerontology Award. This distinguished honor is ... helped bring about a new synthesis and perspective or ...
Cached Medicine News:Health News:Progress made in understanding breast cancer risk 2Health News:Progress made in understanding breast cancer risk 3Health News:Progress made in understanding breast cancer risk 4Health News:Progress made in understanding breast cancer risk 5Health News:Progress made in understanding breast cancer risk 6Health News:Combination of existing safety checks could greatly reduce radiotherapy errors 2Health News:Combination of existing safety checks could greatly reduce radiotherapy errors 3Health News:Binstock wins GSA's 2011 M. Powell Lawton Award 2Health News:Jette to receive GSA's 2011 Excellence in Rehabilitation of Aging Persons Award 2Health News:Kahana to receive GSA's 2011 Distinguished Career Contribution to Gerontology Award 2
(Date:7/31/2014)... DIEGO , July 31, 2014  Sorrento Therapeutics, Inc. ... of Mr. Amar Singh , Chief Business Officer and ... apparent natural causes on July 30. "Sorrento is ... friend and colleague. Our immediate thoughts go to Amar,s family ... and Chief Executive Officer. Mr. Singh joined ...
(Date:7/31/2014)... -- ResMed Inc. (NYSE: RMD ) today announced results ... June 30, 2014.  Revenue for the quarter was $415.2 million, ... 1 percent decrease on a constant currency basis). Net income ... the quarter ended June 30, 2013. Diluted earnings per share ... compared to the quarter ended June 30, 2013.  ...
(Date:7/31/2014)... Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC ) today ... June 30, 2014. Financial Results for the Six ... revenue for the quarter ended June 30, 2014 increased to ... 30, 2013 primarily due to IMBRUVICA ® (ibrutinib) net ... for the six months ended June 30, 2014 increased to ...
Breaking Medicine Technology:Sorrento Announces the Unexpected Death of its Chief Business Officer 2RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 2RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 3RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 4RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 5RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 6RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 7RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 8RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 9RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 10RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 11RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 12RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 13Pharmacyclics Reports Second Quarter 2014 Results 2Pharmacyclics Reports Second Quarter 2014 Results 3Pharmacyclics Reports Second Quarter 2014 Results 4Pharmacyclics Reports Second Quarter 2014 Results 5Pharmacyclics Reports Second Quarter 2014 Results 6Pharmacyclics Reports Second Quarter 2014 Results 7Pharmacyclics Reports Second Quarter 2014 Results 8Pharmacyclics Reports Second Quarter 2014 Results 9Pharmacyclics Reports Second Quarter 2014 Results 10Pharmacyclics Reports Second Quarter 2014 Results 11Pharmacyclics Reports Second Quarter 2014 Results 12Pharmacyclics Reports Second Quarter 2014 Results 13Pharmacyclics Reports Second Quarter 2014 Results 14Pharmacyclics Reports Second Quarter 2014 Results 15Pharmacyclics Reports Second Quarter 2014 Results 16Pharmacyclics Reports Second Quarter 2014 Results 17Pharmacyclics Reports Second Quarter 2014 Results 18Pharmacyclics Reports Second Quarter 2014 Results 19Pharmacyclics Reports Second Quarter 2014 Results 20Pharmacyclics Reports Second Quarter 2014 Results 21Pharmacyclics Reports Second Quarter 2014 Results 22Pharmacyclics Reports Second Quarter 2014 Results 23
... 2011 Abaxis, Inc. (NasdaqGS: ABAX), a medical products company ... to discuss its financial results for the second quarter of ... be at 4:15 p.m. ET on Tuesday, October 25, 2011. ... of fiscal year 2012 after the market closes on Tuesday, ...
... Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL ), a specialty ... on Monday, October 31, 2011 before the opening of the ... call that day at 10:00 a.m. ET to discuss results ... to be used during the call will be available on ...
Cached Medicine Technology:Abaxis to Report Second Quarter Fiscal Year 2012 Financial Results Tuesday, October 25, 2011 2Auxilium Pharmaceuticals to Announce Third Quarter 2011 Results and Conduct Conference Call on Monday, October 31, 2011 2Auxilium Pharmaceuticals to Announce Third Quarter 2011 Results and Conduct Conference Call on Monday, October 31, 2011 3
... The Research pro Electronic Pipette is ideal ... laboratory. Its easy-to-follow display, ergonomically-placed operating buttons, ... dispensing, reverse pipetting and diluting make this ... simple functions of a manual pipette without ...
... Comfort Pick one of our pipettors up ... trigger and ejector positionsright where they should beeven ... ergonomically designed to help avoid repetitive stress injuries ... In The Palm Of Your Hand Start ...
... for Unparalleled Comfort Pick one of our ... Notice the trigger and ejector positionsright where they ... pipettors are ergonomically designed to help avoid repetitive ... Productivity In The Palm Of Your Hand ...
... The Finnpipette BioControl multichannel ... features as the single ... handle fits all seven ... channel tip cone modules. ...
Medicine Products: